Summary

Semax is a synthetic heptapeptide analogue of the adrenocorticotropic hormone (ACTH) fragment 4–10, modified with a C-terminal Pro-Gly-Pro extension to enhance metabolic stability. Research indicates that Semax operates primarily through the upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF), facilitating neurotrophic modulation and neuroprotective effects across various preclinical models. It has been extensively investigated in ischemia and stroke models, where it is associated with reduced infarct volume and improved functional recovery. Furthermore, nasal administration research remains a primary focus in laboratory settings to assess its direct central nervous system access via the olfactory pathway. Within the melanocortin system context, Semax is reported to interact with MC4R and MC5R receptors, distinguishing its activity from the hormonal steroidogenic effects of native ACTH. This review summarizes the current scientific literature regarding Semax peptide and its potential in cognitive research and neuroprotection. All information provided is for research purposes only.

Contents

Introduction: Origin and Design

Semax (Met-Glu-His-Phe-Pro-Gly-Pro) is a synthetic heptapeptide based on the ACTH(4–10) sequence, identified for its neurotropic activity without systemic hormonal effects [1, 3]. To improve metabolic stability, researchers extended the ACTH(4–7) core (Met-Glu-His-Phe) with a Pro-Gly-Pro (PGP) tripeptide "tail" [3]. This modification increases resistance to enzymatic cleavage, particularly by proline-specific endopeptidases, allowing for sustained biological activity in central nervous system models [4].

Stability and Nasal Administration Research

Because peptides exhibit poor oral bioavailability, researchers utilize nasal administration in laboratory paradigms to bypass the blood-brain barrier (BBB) via olfactory and trigeminal nerve pathways. In rodent models, intranasally administered Semax is detected in the brain within minutes, peaking in the hippocampus and prefrontal cortex [4]. This rapid entry is critical for acute neuroprotection studies, such as ischemia-reperfusion injury models.

Mechanism: BDNF and Neurotrophic Modulation

The primary mechanism of Semax is the upregulation of brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). BDNF regulates neuronal survival and synaptic plasticity. Preclinical studies show Semax increases BDNF mRNA expression in the rat hippocampus and frontal cortex [6], likely via CREB activation. This triggers several intracellular cascades:

  • PI3K/Akt Pathway: Promotes survival by inhibiting pro-apoptotic factors [7].
  • MAPK/ERK Pathway: Regulates synaptic protein synthesis and long-term potentiation (LTP) [7, 8].

Semax also modulates dopaminergic and serotonergic systems, increasing turnover in the striatum and hypothalamus [9], which may underpin reported cognitive effects.

The Melanocortin System Context

Semax interacts with MC4R and MC5R subtypes within the melanocortin system, distinguishing it from native ACTH, which primarily activates the adrenal MC2R [10]. Semax acts as a competitive antagonist or partial modulator at these receptors, potentially blocking inflammatory pathways while triggering upstream BDNF expression via adenylate cyclase and cAMP elevation.

Research Domain: Ischemia and Stroke Models

The most extensive body of evidence for Semax neuroprotection comes from studies of cerebral ischemia. Stroke research often utilizes the middle cerebral artery occlusion (MCAO) model in rats to simulate the physiological conditions of an ischemic stroke.

Preclinical Findings in Focal Ischemia

In MCAO models, administration of Semax has been associated with a significant reduction in the volume of the necrotic area (infarct volume) compared to saline-treated controls [1, 11]. Researchers have reported that the peptide's effectiveness is most pronounced when administered shortly after the ischemic event, suggesting a focus on the "penumbra"—the salvagable tissue surrounding the primary core of the stroke.

Histological analysis in these studies often shows a decrease in the density of apoptotic neurons and a reduction in microglial activation. One study utilizing transcriptome analysis reported that Semax modulates the expression of over 50 genes during the acute phase of ischemia, many of which are involved in the inflammatory response and the regulation of vascular permeability [5]. By shifting the gene expression profile away from pro-inflammatory cytokines like IL-6 and toward protective growth factors, the peptide is reported to mitigate the secondary damage that typically follows the initial ischemic insult.

Clinical Research and Rehabilitation

Clinical research in Russia has evaluated Semax in patients with ischemic stroke. A 2018 study involving 110 patients reported that inclusion of Semax in rehabilitation coincided with higher plasma BDNF levels and improved Barthel Index scores [2]. Investigators noted sustained BDNF elevation, which correlated with better motor recovery. While suggestive, the lack of large-scale clinical trials in Western regulatory environments remains a primary research gap.

Research Domain: Cognitive Research and Nootropic Potential

The term "nootropic" is frequently applied to Semax in scientific summaries, referring to its reported ability to enhance cognitive functions such as learning, memory, and attention in animal models.

Learning and Memory

In behavioral studies, Semax-treated rats show improved spatial navigation (e.g., Morris Water Maze) and conditioned avoidance [6]. These improvements relate to enhanced Long-Term Potentiation (LTP) in the hippocampus. Since BDNF regulates LTP, the link between molecular mechanisms and behavioral outcomes is central to Semax research [3, 8].

Neurodegenerative Models

Research has expanded into Huntington's disease models, where Semax is reported to prevent striatal neuron death and preserve coordination [7]. In Alzheimer's models, investigators study its ability to protect against amyloid-beta toxicity. In ADHD models, Semax improved attention and decreased hyperactivity in Spontaneously Hypertensive Rats (SHR), potentially via dopaminergic modulation.

Comparative Summary of Research Findings

The following table summarizes reported effects of Semax peptide across several research domains.

Research Domain Primary Models Key Reported Findings Efficacy/Certainty
Ischemia/Stroke Rodent MCAO, Clinical Trials Reduced infarct volume, elevated BDNF, improved motor scores [1, 2, 11] High
Cognitive/Learning Morris Water Maze, Avoidance Enhanced LTP, improved spatial memory, structural plasticity [6, 8] Medium-High
Neurodegeneration Huntington's/Alzheimer's Neuronal survival, protection against proteinopathy toxicity [7] Low-Medium
Neuroinflammation Cytokine models Shift in pro-inflammatory gene expression, reduced microglial active [5, 11] Medium
Vascular Support VEGF studies Upregulation of angiogenic factors in peri-infarct zone [5, 11] Medium

Limitations and Research Considerations

  • Geographic Concentration of Research: The vast majority of published studies on Semax originate from a few institutions in Russia. While the findings are consistent, there is a lack of independent replication by laboratories in North America or Western Europe.
  • Model Dependency: As with many neuroprotective agents, findings in rodent models do not always translate to human biology. The complexities of the human brain's inflammatory response to stroke may differ significantly from the standardized MCAO model.
  • Variable Dose-Response Data: While many studies report a bell-shaped dose-response curve for Semax—meaning more is not necessarily better—the exact "ideal" research concentration varies widely between different cognitive and neuroprotective paradigms.
  • Pharmacokinetic Gaps: While nasal administration research provides a pathway for CNS entry, the long-term metabolic fate of the peptide and its metabolites remains incompletely characterized.
  • Regulatory Status: Semax is not approved by the FDA or EMA for any clinical indication. It is strictly a laboratory compound for research use only. Investigators must ensure compliance with all local and institutional regulations regarding the handling of synthetic peptides.

Sourcing Semax for Laboratory Research

When sourcing Semax for laboratory investigation, researchers must prioritize chemical identity and purity. Due to the peptide's sensitivity to enzymatic degradation, ensuring the presence of the Pro-Gly-Pro (PGP) tail is essential for experimental validity. Laboratories should always verify materials against a third-party Certificate of Analysis (COA).

For high-quality research materials, several suppliers provide Semax with verified testing:

For more information on selecting a reliable partner, refer to our supplier evaluation guide or browse our Trusted Research Suppliers and Supplier Reviews. Comprehensive reviews of other neuropeptides and repair factors, such as BPC-157 and TB-500, are also available for comparison in multi-peptide experimental designs.

Frequently Asked Research Questions (FAQ)

What is Semax peptide?

Semax is a synthetic heptapeptide derived from the N-terminal fragment of the adrenocorticotropic hormone (ACTH). It was specifically engineered to enhance neuropeptide stability and provide neuroprotective effects without the hormonal side effects associated with the full-length ACTH molecule. It is primarily utilized in cognitive research and ischemic stroke models.

What is the relationship between Semax and ACTH?

Semax is a synthetic analogue of the ACTH(4–10) fragment. By extending the core ACTH(4–7) sequence with a Pro-Gly-Pro tripeptide, researchers created a compound that retains the neurotropic properties of the parent hormone while gaining significant resistance to enzymatic degradation, allowing for more durable effects in central nervous system research.

How does Semax interact with BDNF?

Published studies indicate that Semax upregulates the expression of Brain-Derived Neurotrophic Factor (BDNF) and its receptor, TrkB, particularly in the hippocampus. This interaction facilitates neurotrophic modulation, supporting neuronal survival, dendritic spine formation, and synaptic plasticity, which are critical components of research into learning and memory enhancement.

What is reported in Semax ischemia research?

In preclinical ischemia and stroke models, Semax has been associated with a reduction in infarct volume and the preservation of neuronal integrity in the peri-infarct zone. Research suggests the peptide modulates the post-ischemic inflammatory response and enhances the expression of neurotrophic factors, contributing to accelerated functional and motor recovery.

Is Semax stable in laboratory settings?

Yes, the addition of the C-terminal Pro-Gly-Pro extension significantly enhances the peptide's metabolic stability compared to native ACTH fragments. This structural modification protects the molecule from rapid cleavage by endopeptidases, making it a reliable subject for research involving nasal administration or prolonged cellular exposure in vitro.

Is Semax approved for clinical research in the US?

No. While Semax is included in the Russian List of Vital & Essential Drugs for various cerebrovascular indications, it is not approved by the U.S. Food and Drug Administration (FDA) for any therapeutic use. It remains categorized as a research-use-only (RUO) compound in the United States and most other territories.

Works Cited

  1. Gusev EI, Skvortsova VI, Miasoedov NF, et al. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. PMID: 11517472.
  2. Gusev EI, Martynov MY, Kostyuchenko VV, et al. The efficacy of Semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3. Vyp. 2):61-68. doi:10.17116/jnevro20181183261-68. PMID: 29798983.
  3. Shadrina MI, Slominsky PA, Limborska SA. Molecular mechanisms of the action of the peptide Semax in the brain. Mol Biol (Mosk). 2010;44(6):993-1000. PMID: 21322967.
  4. Stavchansky VV, Tsibezov VV, Tvorogova TV, et al. Pharmacokinetics and tissue distribution of N-terminal fragment of ACTH(4-7) and its analogue Semax in rats. Bull Exp Biol Med. 2011;151(5):610-613. doi:10.1007/s10517-011-1393-2. PMID: 22442805.
  5. Medvedeva EV, Dmitrieva VG, Povarova OV, et al. The peptide semax affects the expression of genes related to the immune system in rat brain focal ischemia. Genome Biol. 2014;15(4):R64. doi:10.1186/gb-2014-15-4-r64. PMID: 24755106.
  6. Agapova TY, Agapov II, Levitin MY, et al. The effect of the peptide SEMAX on BDNF level in the rat hippocampus. Mol Biol (Mosk). 2007;41(6):1038-1043. PMID: 18197771.
  7. Dolotov OV, Eremin KO, Andreeva LA, et al. Semax prevents the death of neurons in a rat model of Huntington's disease and increases BDNF expression. J Mol Neurosci. 2015;55(1):153-159. doi:10.1007/s12031-014-0370-1. PMID: 25070059.
  8. Kaplan AY, Kochetova AG, Nezavibat'ko VN, et al. No-effect of the adrenocorticotropic hormone fragment ACTH[4-7]-Pro-Gly-Pro (semax) on human psychophysiological indices under multi-stress conditions. Zh Vyssh Nerv Deiat Im I P Pavlova. 1996;46(4):713-719. PMID: 8967332.
  9. Shevchenko MY, Grivennikov SI, Dolotov OV, et al. Semax and its C-terminal fragment Pro-Gly-Pro activate the dopaminergic and serotonergic systems of the brain. Neurosci Behav Physiol. 2006;36(5):489-494. doi:10.1007/s11055-006-0046-1. PMID: 16752079.
  10. Koroleva SV, Ashmarin IP. Mechanism of the action of Semax: search for specific receptors. Ross Fiziol Zh Im I M Sechenova. 2005;91(7):826-834. PMID: 16259061.
  11. Kolomin T, Shadrina M, Slominsky P, et al. A peptide drug Semax affects the expression of genes involved in the work of the immune system in rats after cerebral ischemia. BMC Genomics. 2013;14(Suppl 7):S14. doi:10.1186/1471-2164-14-S7-S14. PMID: 24564344.
  12. Lebedeva IS, Panikratova YR, Sokolov AS, et al. Effects of Semax on the Functional Connectivity of the Default Mode Network. CNS Neurol Disord Drug Targets. 2018;17(3):214-221. doi:10.2174/1871527317666180411124610. PMID: 29637841.

Disclaimer: This research review is provided for educational and laboratory reference purposes only. Semax is a synthetic peptide intended for in vitro and animal model investigation. It is not approved for human or veterinary use, and no protocols for administration or dosing are provided. Researchers are responsible for ensuring that all laboratory work complies with institutional biosafety guidelines and local regulations.